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PAdrenoreceptor Polymorphism
he Arg389Gly Beta1-Adrenoceptor Polymorphism
nd Catecholamine Effects on Plasma-Renin Activity
eike Bruck, MD, Kirsten Leineweber, PHD, Thomas Temme, Melanie Weber,
erd Heusch, MD, FACC, Thomas Philipp, MD, Otto-Erich Brodde, PHD
ssen, Germany
OBJECTIVES The purpose of this research was to find out whether, in humans, dobutamine-induced
hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-
adrenoceptor (1AR) genotype-dependent.
BACKGROUND In vitro Arg389Gly-1AR polymorphism exhibits decreased receptor signaling.
METHODS We studied 10 male homozygous Arg389-1AR subjects and 8 male homozygous
Gly3891AR subjects; to avoid influences of codon 49 polymorphism, all were homozygous
Ser49-1AR. Subjects were infused with dobutamine (1 to 6 g/kg/min) with or without
bisoprolol (10 mg orally) pretreatment, and PRA, heart rate, contractility, and blood pressure
were assessed.
RESULTS With regard to PRA, dobutamine increased PRA more potently in Arg389-1AR versus
Gly389-1AR subjects. Bisoprolol markedly suppressed the dobutamine-induced PRA increase
in Arg389- but only marginally in Gly389-1AR subjects. With regard to hemodynamics,
dobutamine caused larger heart rate and contractility increases and diastolic blood pressure
decreases in Arg389- versus Gly389-1AR subjects. Bisoprolol reduced dobutamine-induced
heart rate and contractility increases and diastolic blood pressure decreases more potently in
Arg389- versus Gly389-1AR subjects.
CONCLUSIONS Codon 389 1AR polymorphism is a determinant not only of hemodynamic effects but also
of PRA. Thus, 1AR polymorphisms may be useful for predicting therapeutic responses to
AR-blocker treatment. (J Am Coll Cardiol 2005;46:2111–5) © 2005 by the American
























oeta1-adrenoceptors (1ARs) play an important role in
egulation of cardiac function in man; furthermore, they are
nvolved in lipolysis and renin secretion (1). There are two
unctionally important single nucleotide polymorphisms
SNPs) in the 1AR gene: at position 49 serine is substi-
uted by glycine (Ser49Gly), whereby in vitro Gly49-variant
as more susceptible to agonist-mediated down-regulation
han Ser49-variant. At position 389 arginine is substituted
y glycine (Arg389Gly); in vitro Arg389-variant has basal
nd isoprenaline-activated adenylyl cyclase activity three- to
our-fold higher than Gly389-variant; Gly389-variant,
owever, was initially considered the wild-type receptor but
s the minor allele (2–5).
Controversial data exist on functional consequences of
rg389Gly-1AR polymorphism in humans; in isolated
uman tissues, some studies found larger agonist-induced
esponses in Arg389- versus Gly389-1AR, whereas others
ailed to find genotype-dependent differences (5,6). Simi-
arly, in vivo several groups failed to find, in homozygous
rg389- or Gly389-1AR subjects, differences in exercise-
nduced heart rate (HR) increases mediated by cardiac
1AR (6,7). La Rosee et al. (8), however, using a modified
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ccepted August 22, 2005.obutamine stress echocardiography protocol, demonstrated
ecently that homozygous Arg389-1AR subjects exhibited
arger inotropic and blood pressure (BP) responses than
ubjects carrying one or two Gly389 alleles. In contrast to all
xercise studies published so far, however, La Rosee et al.
8) administered dobutamine to subjects pretreated with
tropine to exclude possible counter-regulatory parasympa-
hetic effects.
In contrast to cardiac effects, little is known about the
ossible impact of 1AR polymorphisms on extracardiac
ffects such as renin secretion, that, in humans, is mediated
y renal 1AR (1). We could not find genotype-dependent
ifferences in exercise-induced increase in plasma-renin
ctivity (PRA) in Arg389- versus Gly389-1AR subjects
9). The renin-angiotensin-aldosterone system (RAAS)
lays an important role in BP regulation and is certainly one
arget, out of several, for BP-lowering effects of AR-
lockers (10). Thus, it could well be that antihypertensive
ffects of AR-blockers are modulated by 1AR polymor-
hisms (11).
In this study we determined, in male homozygous
rg389- or Gly389-1AR subjects, the effects of dobut-
mine on PRA and its attenuation by the 1AR selective
locker bisoprolol to find out whether there are genotype-
ependent differences. Studies were performed in the absence
f atropine to find out whether atropine is necessary for
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Arg389Gly 1AR Polymorphism and PRA December 6, 2005:2111–5voked effects (8). Codon 49 SNP can modulate functional
esponsiveness of codon 389 SNP (12); therefore, all sub-
ects participating in this study were homozygous
er49-1AR.
ETHODS
enotyping. To obtain human genomic deoxyribonucleic
cid (DNA), 10 ml of blood was withdrawn in ethylenedi-
minetetraacetic acid (EDTA) tubes, and DNA was ex-
racted with the GenomicPrep Blood DNA Isolation Kit
Amersham Biosciences, Buckinghamshire, United King-
om); 1AR genotypes at codon 49 and 389 were deter-
ined by polymerase chain reaction and subsequent restric-
ion length polymorphism (restriction enzymes Sau96I and
stNI, respectively) with modified protocols from previously
escribed methods (3,4).
xperimental protocol. We genotyped 201 subjects for
1AR codon 49 and 389 SNPs (Ser49Gly and Arg389Gly);
8 male subjects participated in the study (Table 1). Ten
ere homozygous Arg389 (mean age 25 3 years), eight were
omozygous Gly389 (mean age 25  3 years), and all were
omozygous Ser49.
All study participants gave written informed consent. The
thical committee of the University of Essen Medical School
pproved the study protocol. Subjects were in normal health,
ased on cardiovascular and other medical history, physical
xamination, and biochemical, hematologic, and electrocar-
iographic screening. No subjects took any medication, and
ll were nonsmokers. Subjects and investigators were
Abbreviations and Acronyms
1AR  beta1-adrenoceptor
BP  blood pressure
DBP  diastolic blood pressure
HR  heart rate
PRA  plasma-renin activity
QS2c  heart rate-corrected duration of the
electromechanical systole
RAAS  renin-angiotensin-aldosterone system
SBP  systolic blood pressure
SNP  single nucleotide polymorphism
Table 1. Baseline Parameters in Subjects Hom
After Oral Pretreatment With 10 mg Bisoprol
Arg389 1AR (n 
Before After
PRA (ng/ml/h) 1.5  0.2 0.
HR (beats/min) 53  2 4
BPsyst (mm Hg) 119  3 11
BPdiast (mm Hg) 75  4 7
QS2c (ms) 511  6 51
Baseline parameters were assessed after 1 h of rest in supine posit
section). Mean  SEM of 10 (Arg389) and 8 (Gly389) experi
AR  adrenoceptor; 1AR  beta1-adrenoceptor; BPdias
 heart rate; ng/ml/h  ng angiotensin I formed/ml/h; PRA  p
of electromechanical systole.linded for 1AR haplotype. All subjects were studied in
he morning in supine position after an overnight fast.
ubjects were advised to avoid caffeine, alcohol, and physical
xercise before each study. Room temperature was kept
table between 24°C to 26°C.
Subjects were studied on two separate days with at least a
ne-week interval; after arrival at the clinical laboratory at
:30 AM and after affixment of instruments, indwelling
olythene catheters were positioned in right and left ante-
ubital veins. Blood samples were drawn from the right arm;
rugs were separately administered in the left arm.
After 1 h of rest in the supine position, subjects were
ntravenously infused with dobutamine (DobutaminSolvay/
olvay Arzneimittel, Hannover, Germany) in doses of 1, 2,
, and 6 g/kg/min for 15 min each (13). For bisoprolol
Concor, Merck, Darmstadt, Germany) experiments, sub-
ects received a 10-mg tablet orally 150 min before the
nfusion started.
We assessed PRA and cardiovascular effects of dobut-
mine immediately before bisoprolol intake, immediately
efore start of infusion, and during the last 5 min of each
obutamine dose. Cardiovascular effects were assessed by
etermining systolic (SBP) and diastolic BP (DBP), HR,
nd systolic time intervals exactly as described elsewhere (9).
rom systolic time intervals, only data for HR-corrected
uration of electromechanical systole (QS2c) are shown,
hich is the most sensitive parameter for contractility
hanges (14).
For PRA and plasma bisoprolol determination, 10-ml
ce-cold EDTA blood was withdrawn at the given time
oints; PRA was assessed by radioimmunoassay (DiaSorin,
aluggia, Italy), and bisoprolol plasma levels were assessed
y the high-pressure liquid chromatography method.
tatistics. Data given in text and figures are mean values
EM of the number of experiments. Differences between
aseline values of HR, QS2c, SBP, DBP, and PRA were
ssessed by the unpaired two-tailed Student t test.
Dose-response curves of dobutamine-induced changes in
R, contractility, BP, and PRA were analyzed by factorial
nalysis of variance (ANOVA) (factors: dobutamine dose
nd bisoprolol pretreatment or haplotype) with Bonferroni’s
ost-test for multiple comparisons.
ous for Arg389- or Gly389-1AR Before and
Gly389 1AR (n  8)
prolol Before After Bisoprolol
.2* 1.5  0.2 0.8  0.1*
* 51  3 45  2*
* 121  3 114  4*
77  1 75  2
513  4 515  2
150 min after oral application of 10 mg bisoprolol (seeMethods
. *p  0.05 vs. corresponding values before bisoprolol.
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December 6, 2005:2111–5 Arg389Gly 1AR Polymorphism and PRAEffects of maximum dobutamine dose or bisoprolol on
esting parameters were analyzed by a paired two-tailed
tudent t test.
To assess bisoprolol effects on dobutamine-induced changes
n HR, contractility, BP, and PRA for each dobutamine dose,
ndividual differences in hemodynamic or PRA changes
easured in the presence and absence of bisoprolol were
alculated and analyzed by factorial analysis of variance
factors: dobutamine dose and haplotype) with Bonferroni’s
ost-test for multiple comparisons.
Power calculations for the primary end point, a delta
aximal PRA increase of 1.0 ng angiotensin I formed/ml/h,
evealed with the given number of 10 Arg389-1AR and 8
ly389-1AR subjects a power of 75%. Statistical calcula-
ions were performed with GraphPad Prism 4.0 and Graph-
ad StatMate 2.0 programs (GraphPad Software, San
iego, California). A p value 0.05 was considered statis-
ically significant.
ESULTS
rom 201 subjects genotyped, 53% were homozygous
rg389, 10% homozygous Gly389, and 37% heterozygous
rg389Gly; thus, allele frequencies with Gly as a minor
llele (f() 0.28) were in agreement with previous reports
nd in Hardy-Weinberg equilibrium (5,6,8,9).
Basal hemodynamic parameters and PRA were not sig-
ificantly different between Ser49Arg389-1AR and
er49Gly389-1AR subjects (Table 1).
ffects of dobutamine. PRA. Dobutamine infusion caused
ose-dependent PRA increases that were significantly larger
n Arg389- versus Gly389-1AR subjects (Fig. 1). Maximal
RA increase was 1.56  0.32 ng angiotensin I formed/
l/h in Arg389- and 0.60 0.20 ng/ml/h in Gly389-1AR
ubjects (p  0.05, Bonferroni adjustment with four com-
arisons) (Fig. 1).
R, CONTRACTILITY, AND BP. Dobutamine infusion dose-
ependently increased HR (Fig. 2), contractility (QS2c)
Fig. 2), and SBP (Fig. 3), and decreased DBP (Fig. 3).
Maximal increases in HR (12.9 2.0 beats/min vs. 5.2
.5 beats/min) and contractility (97.0 4.6 ms vs.79.1
.1 ms) were significantly larger in Arg389- versus Gly389-
1AR subjects. A similar tendency of larger effects in
rg389- versus Gly389-1AR subjects was also found for
obutamine-induced maximal DBP decreases, but this did
ot reach statistical significance. Maximal SBP increases,
owever, showed no genotype-dependent difference (Fig. 3).
ffects of bisoprolol on dobutamine effects. A total of
50 min after 10 mg bisoprolol orally, plasma bisoprolol
evels were 48.5  5.3 ng/ml in Arg389- and 49.7  1.9
g/ml in Gly389-1AR subjects.
Bisoprolol significantly decreased basal PRA, HR, and
BP, slightly prolonged QS2c, but only marginally affected
BP (Table 1).
Bisoprolol markedly suppressed the dobutaminenfusion-induced PRA increase in Arg389-1AR subjects Put did not significantly affect the dobutamine-induced
weak) PRA increase in Gly389-1AR subjects (Fig. 1).
Moreover, bisoprolol markedly suppressed the dobutamine
nfusion-induced HR increase in Arg389-1AR subjects, but
id not significantly affect the (weak) dobutamine-inducedHR
ncrease in Gly389-1AR subjects (Fig. 2).
Similarly, bisoprolol reduced the dobutamine-induced
ontractility increase and DBP decrease at most dobutamine
oses more pronounced in Arg389- versus Gly389-1AR
ubjects, although this was not statistically significant at all
obutamine doses (Figs. 2 and 3). Attenuation of the
obutamine-induced SBP increase by bisoprolol, however,
as not genotype-dependent (Fig. 3).
ISCUSSION
he new finding of this study is that the 1AR agonist
obutamine evoked, via renal 1AR stimulation (1), signif-
cantly larger PRA increases in homozygous Arg389-1AR
ubjects than in homozygous Gly389-1AR subjects. More-
ver, the 1AR-blocker bisoprolol inhibited dobutamine-
voked PRA increases significantly more potently in
rg389- versus Gly389-1AR subjects. This might have
mportant clinical implications: AR-blockers are first-line
rugs for treatment of hypertension. Although the experi-
nce of antihypertensive treatment with AR-blockers has
xisted for nearly 40 years, the mechanism of their BP-
owering effects is still not completely understood (10).
mong various hypotheses, RAAS inhibition might play an
mportant role. Thus, various authors showed that BP-
owering effects of AR-blockers were better the higher
igure 1. Dobutamine infusion-induced plasma-renin activity (PRA)
ncrease in 10 healthy homozygous Arg389-beta1 adrenoceptors (1AR)
ubjects (squares) and 8 homozygous Gly389-1AR subjects (circles)
efore (closed symbols) and after (open symbols) treatment with biso-
rolol (1 10 mg orally 150 min before infusion). Ordinate: PRA increase
n  ng angiotensin I formed/ml/h. Abscissa: dobutamine dose in g/kg/
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Arg389Gly 1AR Polymorphism and PRA December 6, 2005:2111–5hat Arg389-1AR patients should have a good response to
AR-blocker treatment, whereas Gly389-1AR patients
hould be poor or non-responders.
In our study dobutamine evoked larger HR and contrac-
ility increases in Arg389- than in Gly389-1AR subjects,
n accordance with recent findings in chronic heart failure
hat exercise capacity was significantly better in Arg389-
han in Gly389-1AR patients (15). Similarly, La Rosee et
l. (8) found, in subjects pretreated with atropine, that those
igure 2. Dobutamine infusion-induced heart rate (HR) (left) and contrac
ubjects (squares) and 8 homozygous Gly389-1AR subjects (circles) befo
0 mg orally 150 min before infusion). Ordinates, left: heart rate (HR) incr
f electromechanical systole [QS2c] shortening) in  ms. Abscissa: dobuta
igure 3. Dobutamine infusion-induced systolic blood pressure (BPsyst
omozygous Arg389-1-adrenoceptor (AR) subjects (squares) and 8 homo
ymbols) treatment with bisoprolol (1  10 mg orally 150 min before infusion)
mm Hg. Abscissa: dobutamine dose in g/kg/min for 15 min each. BL  bomozygous Arg389-1AR exhibited larger SBP and con-
ractility responses to dobutamine than those carrying one
r two Gly389 alleles. Our data now clearly show that
tropine pretreatment is not necessary because also in the
bsence of atropine dobutamine caused significantly larger
ardiac effects in Arg389- versus Gly389-1AR subjects.
In contrast to 1AR genotype-dependent dobutamine
ffects ([8], present data), in several studies exercise-induced
R and contractility increases were not different between
ncreases (right) in 10 healthy homozygous Arg389-1-adrenoceptor (AR)
losed symbols) and after (open symbols) treatment with bisoprolol (1 
n  beats/min (bpm), right: contractility increase (HR-corrected duration
dose in g/kg/min for 15 min each. BL  baseline.
and diastolic blood pressure (BPdiast) changes (right) in 10 healthy
s Gly389-1AR subjects (circles) before (closed symbols) and after (opentility i
re (c) (left)
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December 6, 2005:2111–5 Arg389Gly 1AR Polymorphism and PRArg389- and Gly389-1AR subjects (6). Preliminary data
rom our group indicate that this also holds true for subjects
reated with atropine.
The reason for this discrepancy in cardiac responses to
xercise versus dobutamine is not completely understood.
owever, it should be considered that: 1) responses to
xercise are strongly dependent on the physical fitness of test
ubjects, and it is extremely difficult to precisely control for
hat. Hence, subjects participating in exercise studies may be
f different physical fitness, and that would evoke unpre-
ictable results. 2) Exercise may induce more physiologic
esponses, whereas dobutamine infusion may induce more
harmacologic responses. 3) In all exercise studies published
o far, subjects were not controlled for codon 49 SNP.
odon 49 SNP, however, can modulate functional respon-
iveness of codon 389 SNP; accordingly, 1AR haplotype
nalysis could be more important than single SNP analysis
12,16). Thus, differences obtained in exercise versus dobut-
mine studies could also be due to 1AR haplotype inho-
ogeneity of study groups. In our study, however, all
ubjects were homozygous Ser49-1AR.
Recent evidence suggested that subjects exhibited larger
P and HR responses to 1AR-blockers if they carried
rg389-1AR, and this could be modulated by codon 49
NP (11,16). Similarly, in chronic heart failure, long-term
AR-blocker treatment improved left ventricular ejection
raction significantly better in Arg389- than in Gly389-
1AR patients (17,18). However, no genotype-dependent
ifferences during AR-blocker treatment were also pub-
ished (19,20). In our study bisoprolol inhibited all
obutamine-induced hemodynamic changes, with the ex-
eption of SBP changes, in Arg389-1AR subjects more
otently than in Gly389-1AR subjects. Thus, our data
ight be taken as a further indication that 1AR polymor-
hisms might predict hemodynamic responses to AR-
locker treatment (11).
onclusions. Dobutamine infusion causes larger PRA,
R, and contractility increases in Arg389- than in Gly389-
1AR subjects. In addition, the 1AR-blocker bisoprolol
nhibited PRA and cardiac responses to dobutamine more
otently in Arg389- versus Gly389-1AR subjects. Thus,
1AR polymorphisms may be useful to predict therapeutic
esponses to AR-blocker treatment.
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